AI underweights weigh on large-cap funds performance says Goldman
Sean Murphy, Chief Manufacturing, Strategy & Business Development Officer and Director at TriSalus Life Sciences Inc. (NASDAQ:TLSI), recently acquired a significant amount of common stock in the company. According to a recent SEC filing, Murphy purchased a total of 30,000 shares over two days, January 27 and January 28, 2025. The shares were acquired at a weighted average price range between $5.17 and $5.31, amounting to a total transaction value of approximately $157,200.
Murphy’s transactions have increased his indirect ownership, held through a trust, to 197,732 shares. Additionally, the filing notes that Murphy was awarded 12,500 restricted stock units, which will vest in four equal annual installments starting January 1, 2025, contingent on his continued service with the company. Unlock deeper insights into TLSI’s insider trading patterns and financial health metrics with InvestingPro, which offers exclusive analysis and real-time data.
These purchases reflect Murphy’s growing stake in TriSalus, a company specializing in surgical and medical instruments and apparatus. The company has demonstrated impressive revenue growth of 67.9% and maintains strong gross profit margins of 87.1%, while operating with a healthy current ratio of 2.4.
In other recent news, TriSalus Life Sciences has witnessed significant growth and strategic changes. The medical technology company reported a 59% increase in its 2024 revenue, reaching approximately $29.4 million, largely driven by its TriNav Infusion System. Fourth-quarter earnings also saw a rise of 44%, reaching $8.3 million. The company anticipates this trend to continue, projecting a revenue growth of over 50% for 2025.
TriSalus has also seen changes in its leadership, appointing James Young as Chief Financial Officer, Dr. Richard Marshak as Chief Commercial Officer, and Jodi Devlin as Chief of Clinical Strategy and Operations. The company also launched the TriNav Large system, a medical device expected to cater to 30% more cases than its predecessor.
Analysts have shown interest in the company’s performance. Canaccord Genuity maintained a Buy rating on TriSalus shares, adjusting the price target to $11.00. Similarly, Roth/MKM initiated coverage with a Buy rating, highlighting the potential of TriSalus’s TriNav catheter and Pressure Enabled Drug Delivery technology. Northland also initiated coverage with an Outperform rating, citing the potential of the TriNav system.
Finally, TriSalus is expanding its platform through the integration of the TriNav catheter with a proprietary TL-9 antagonist, currently undergoing phase 1 evaluation. These are the recent developments in TriSalus Life Sciences.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.